x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012950
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro86 of human UQCRFS1/RISP protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | UQCRFS1 |
| UniProt No. | P47985 |
| Gene ID | 7386 |
| Gene Description | Ubiquinol-cytochrome c reductase iron-sulfur subunit, also known as Rieske iron-sulfur protein, is a component of Complex III in the mitochondrial electron transport chain. UQCRFS1/RISP and two other subunits, cytochrome b and cytochrome c1, are essential for the catalytic activity of Complex III. Studies show that UQCRFS1/RISP is required for fetal mouse hematopoietic stem cell differentiation and adult mouse hematopoietic stem cell quiescence. In addition, loss of UQCRFS1/RISP decreases the strength of T cell receptor signaling, indicating that this protein is critical for optimal TCR signaling. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
